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Abstract 
The glutamate metabotropic receptor 1 
(GRM1) drives oncogenesis when aberrantly 
activated in melanoma and several other cancers. 
Metabolomics reveals that patient-derived 
xenografts with GRM1-positive melanoma tumors 
exhibit elevated plasma glutamate levels associated 
with metastatic melanoma in vivo. Stable isotope 
tracing and GCMS analysis determined that cells 
expressing GRM1 fuel a substantial fraction of 
glutamate from glycolytic carbon. Stimulation of 
GRM1 by glutamate leads to activation of mitogenic 
signaling pathways, which in turn increases the 
production of glutamate, fueling autocrine feedback. 
Implementing a rational drug-targeting strategy, we 
critically evaluate metabolic bottlenecks in vitro and 
in vivo. 
Combined inhibition of glutamate secretion 
and biosynthesis is an effective rational drug 
targeting strategy suppressing tumor growth and 
restricting tumor bioavailability of glutamate. 
 
Introduction 
The metabotropic glutamate receptors 
(GRMs) are seven pass transmembrane G-protein-
coupled-receptors (GPCR) that elicit intracellular 
signaling upon binding extracellular glutamate 1-4. 
Though well characterized in the context of excitatory 
neurotransmission in the central nervous system, 
GRM-mediated signaling is now understood to play a 
role in several neuronal and non-neuronal 
pathologies, including cancer 5-9. Elevated tumor 
expression of GRMs has been reported not only in 
central nervous system tumors where glutamate is 
abundant, but also in melanoma, breast, and prostate 
cancers 10-13. The neuroectodermal origin of 
melanocytes, pigment producing cells that migrated 
and differentiated from the neural crest into the skin, 
might be of particular relevance in malignant 
melanoma 14. Metastases to the central nervous 
system are among the most common and lethal 
complications of metastatic melanoma. Melanoma is 
the third most common source of brain metastases 
following lung and breast cancer and more than 60% 
of patients with metastatic melanoma either present 
with or develop brain metastases during the course of 
their disease. 
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The first direct link between the glutamate 
metabotropic receptor 1 (GRM1) and oncogenesis 
came from a transgenic mouse model of melanoma 
ectopically expressing GRM1 15-17. Since then, it has 
been reported that 80% of human melanoma cell 
lines and 65% of primary and secondary melanoma 
biopsies express GRM1 10. GRM1 overexpression is 
sufficient to induce oncogenic transformation, and 
pharmacological inhibition of GRM1 in high 
expressing tumors slows proliferation and tumor 
progression 10,15,18-21. Stimulation of GRM1 signaling 
by glutamate or other agonists results in activation of 
oncogenic signaling pathways including mitogen 
activated protein kinase (MAPK), phosphatidylinositol 
3-kinase (PI3K) and serine/threonine kinase AKT, and 
insulin-like growth factor 1 (IGF1) 10,15,22-24. These and 
other results indicate that GRM1 is an oncogene that 
may serve as an attractive therapeutic target 25, 
especially in melanoma subtypes, where well-
characterized drug targets beyond the MAPK 
pathway are missing. Metabolic rewiring, including 
increased glucose and glutamine consumption, is a 
prominent feature of malignant melanoma 26-29. 
GRM1 expressing cells increase the production and 
release of glutamate, thereby engaging in an 
autocrine loop involving leading to increased GRM1 
mediated oncogenic signaling 10,30-32. Given metabolic 
similarity of the five-carbon amino acids glutamate 
and glutamine and their relatively direct conversion 
by deamination, the L-glutamine amidohydrolase, 
glutaminase (GLS), has been suggested as carbon 
bottleneck and anti-cancer drug target. 
Treatment with riluzole, which blocks 
glutamate release, disrupts GRM1 mediated signaling 
and exhibits anti-tumor properties. 
Pharmacologically, bioavailability and molecular 
targeting of glutamate metabolism are active areas of 
research, despite the exact mechanism of how 
riluzole inhibits the release of glutamate is 
biochemically unknown. Preclinical studies with 
riluzole, which serves as an indirect antagonist of 
GRM1 and blocks glutamate release, led to decreased 
melanoma cell growth in vitro and tumor progression 
in vivo 19 33-37. Understanding the metabolic pathways 
employed by GRM1-activated melanoma to increase 
glutamate production may lead to the development 
of rational drug combinations targeting aberrant 
GRM1 signaling and its accompanying metabolic 
rewiring. With applicable experimental cellular and 
animal model systems in hand (Figure 1), we sought 
to elucidate the metabolic source of activated 
glutamate in GRM-activated tumors and to design a 
rational drug targeting strategy of glutamate 
metabolism in malignant melanoma. 
Methods 
Constructing isogenic melanoma models 
with modulated GRM1 expression 
We metabolically profiled circulating blood 
from tumor-bearing xenograft animals as well as the 
source panel of isogenic human melanoma cell lines 
engineered to have increased or suppressed GRM1. 
Patient-derived human melanoma cell lines were 
provided by Dr. Mary J.C. Hendrix (Children’s 
Memorial Research Center, Chicago, IL). C81-61 is an 
early stage melanoma cell line, which does not 
express endogenous GRM1. C8161 is a malignant 
metastatic melanoma cell line from the same patient 
as C81-61 but with hyperactive GRM1. A stable C8161 
TetR GRM1 siRNA knockdown B22-20 clone was 
generated and maintained in 1 μg/ml blasticidin and 
10 μg/ml hygromycin 19. Induction of siRNA against 
GRM1 was carried out by incubating the cells with 
10 ng/ml of doxycycline for 4 days. Stable C81-61OE 
GRM1-6 clone that expresses elevated GRM1 levels 
compared to parental cell lines was selected with 
10 μg/ml blasticidin 38. These cell lines were cultured 
in DMEM (10-017, Corning Cell-Gro, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS), 1% 
Penicillin-Streptomycin (30-002-CI, Corning Cell-Gro, 
Manassas, VA), and 1% MEM Non-Essential Amino 
Acids (25-025-C, Corning Cell-Gro, Manassas, VA) at 
37.0 °C (310.15 K) with 5.0% carbon dioxide (CO2, 
CD50, Praxair, Danbury, CT). Together, the panel of 
human cell lines, C81-61 (GRM1—), C8161si TetR 
siRNA(GRM1) (GRM1KD), C81-61OE (GRM1OE), and 
C8161 (GRM1+) provide a patient-derived isogenic 
progression model of NF1/NRAS/BRAF triple wild-
type melanoma (Figure 1). 
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The 1205LU (ATCC CRL-2812) model was 
provided by Dr. Meenhard Herlyn (Wistar Institute, 
Philadelphia, PA) and is derived from lung metastases 
of primary melanoma lesion WM793B cells (ATCC 
CRL-2806) after subcutaneous injection into 
immunodeficient mice. 1205LU cells are highly 
invasive and exhibit spontaneous metastasis to lung 
and liver 39. The WM793B line was established from 
skin taken from the primary melanoma of a vertical 
growth phase (VGP) lesion taken from the sternum of 
a patient on 01/07/1983. 
The transgenic founder strain 3 (TG3) with 
hyperactive Grm1+ was crossed with hairless SKH-1 
mice to arrive at the TGS strain—brother-sister 
littermates have been mating since the year 2000. 
TG3 mice were established as a result of a classic case 
of insertional mutagenesis that led to the ectopic 
expression of Grm1 in melanocytes. TG3 mice 
spontaneously develop metastatic melanoma with 
100% penetrance. SKH-1 is an uncharacterized/non-
pedigreed hairless strain of mice. The goal was to 
make the pigmented lesions visible on the TGS mice 
in the absence of fur. TGS mice were genotyped by 
DNA extraction and subsequent PCR of the Grm1 
locus. 
Toxicology and inhibitor studies 
The inhibitory concentration 50% (IC50), the 
concentration of drug that is required for 50% 
inhibition of cell proliferation in vitro, was 
determined in 384 plate-based cell proliferation 
assays at 450 nm absorption. After 24 h incubation, 
cells were equilibrated at room temperature before 
being treated with 50 μL/well of CellTiter-Glo 
luminescent cell viability assay (CTG, G7571, 
Promega, Madison, WI). The number of viable cells 
relative to control cells, results in an accompanying 
change in the amount of formazan formed using a 
saturated aqueous 1.0 mg/mL solution of 2,3-bis[2-
methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-
carboxyanilide sodium salt (XTT, X4626, Millipore 
Sigma, Darmstadt, Germany), indicating electron-
dependent redox changes or the degree of 
cytotoxicity caused by the test compounds. The 
compounds were dissolved as stock solutions in 
dimethyl sulfoxide (DMSO, D2650, Millipore Sigma, 
Darmstadt, Germany) or water and compared to the 
vehicle-treated control conditions. Cells were plated 
in black walled, clear bottom 384 well plates at a 
density of 500 cells per well in 50 μL of supplemented 
MEM. After 24 h, 5 μL of a 2-fold dilution series of 
each chemical inhibitor in supplemented MEM was 
added to wells in quadruplicate (N=4). Cells were then 
shaken for 2.0 min and incubated for 8.0 min 
protected from light before the luminescence is being 
analyzed in a multi-mode microplate reader (Synergy 
HT, BioTek, Winooski, VT). 
Tested compounds included Bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide; 
2,2'-(5,5'-(2,2'-thiobis(ethane-2,1-diyl))bis(1,3,4-
thiadiazole-5,2-diyl))bis(azanediyl)bis(1-
phenylethanone (BPTES, PubChem CID: 3372016, 
SML0601), deferoxamine mesylate (PubChem CID: 
62881, D9533), sodium oxamate (PubChem CID: 
5242, O2751), dichloroacetic acid (DCA, PubChem 
CID: 6597, 347795), 5-aminoimidazole-4-
carboxamide 1-beta-D-ribofuranoside (AICAR, 
PubChem CID: 46780289, A9978), 2-deoxy-D-glucose 
(2DG, D6134) and 2-cyano-3-(1-phenylindol-3-
yl)acrylate (UK5099, PubChem CID: 6438504, PZ0160, 
all Millipore Sigma, Darmstadt, Germany), 2-(pyridin-
2-yl)-n-(5-(4-[6-(([3-
(trifluoromethoxy)phenyl]acetyl)amino)pyridazin-3-
yl]butyl)-1,3,4-thiadiazol-2-yl)acetamide (CB839, 
PubChem CID: 71577426, Medchemexpress, 
Monmouth Junction, NJ), and 6-(trifluoromethoxy)-
1,3-benzothiazol-2-amine (riluzole, PubChem CID: 
5070, Selleckchem, Houston, TX). 
Xenograft studies and tumorigenicity assays 
C8161 and 1205LU human melanoma cells 
were harvested by trypsinization and resuspended in 
phosphate based saline (PBS) (107 cells/ml). 5 to 6-
week-old immunodeficient nude male and female 
mice were subcutaneously injected with 106 tumor 
cells in each dorsal flank. Tumor cell lines for 
xenograft studies were cultured in RPMI-1640 
medium supplemented with 10% FBS. Tumor growth 
was monitored weekly with a vernier caliper and 
calculated with the formula (d2 · D/2). CB839 (50 mM 
_____________________________________________________________________________________ 
GRM1  Page 4 of 15 
stock solution), riluzole (100 mM stock solution) and 
UK5099 (50 mM stock solution) were dissolved in 
DMSO. Once tumor volumes reached 10 to 20 mm3, 
mice were randomly divided into four treatment 
groups and received control vehicle DMSO, riluzole 
(10 mg/kg), CB839 (200 mg/kg), or the combination 
of riluzole (10 mg/kg) and CB839 (200 mg/kg) by oral 
gavage, daily. UK5099 was administered via 
intraperitoneal injection (3 mg/kg). The experiment 
was terminated when the xenografts in the vehicle 
group reached maximum permitted size. All animal 
procedures and xenograft studies were performed in 
strict accordance with the institutional animal care 
and use committee (IACUC). 
Blood collection 
Heparinized microhematocrit capillary tubes 
(22-362-566, Thermo Fisher Scientific, Waltham, MA) 
were used to retro-orbitally bleed mice. About 300 µL 
of blood was collected per mouse at each time-point 
and kept on ice. Samples were centrifuged for 8 min 
at 104 rpm at 4 °C (277.15 K). Plasma supernatant was 
separated from the red blood cell pellet and stored at 
-80 °C (193.15 K). 
Immunohistochemistry 
Sectioning, staining and quantitative image 
analysis of formalin-fixed, paraffin-embedded (FFPE) 
tumor and liver tissues were performed using a fully 
automated workflow according to standard operating 
procedures (Histowiz, Brooklyn, NY). Briefly, tissue 
samples were processed and embedded in paraffin 
blocks and then shipped out to the pathology lab on 
ice where subsequent sectioning at 4 μm and 
Immunohistochemistry (IHC) was piloted. FFPE liver 
sections were stained with hematoxylin and eosin 
(H&E). IHC on FFPE tumor tissue was performed on a 
Bond Rx autostainer (Leica Biosystems, Nussloch, 
Germany) with enzyme treatment (1:1000) using 
standard protocols. Bond polymer refine detection 
(Leica Biosystems, Nussloch, Germany) was used 
according to standard operating procedures. After 
staining, sections were dehydrated and film cover-
slipped using a TissueTek-Prisma and Coverslipper 
(Sakura Finetek, Torrance, CA). Whole slide scanning 
(40x magnification) was performed on an Aperio AT2 
(Leica Biosystems, Nussloch, Germany). Unbiased 
automated image analysis to obtain percentage of 
marker of proliferation Ki-67+ (MKI67) and cleaved 
apoptosis marker executioner caspase 3+ (CASP3) 
cells was performed using the HALO image analysis 
software by Indica Labs, Albuquerque, NM). 
Western immunoblots 
Polyclonal anti-GRM1 antibody was 
purchased from Lifespan BioSciences (LS-C354444, 
Seattle, WA). Polyclonal anti-GLS antibody was 
purchased from Novus Biologicals (NBP1-58044, 
Littelton, CO). Monoclonal anti-α-tubulin antibody 
was purchased from Sigma Aldrich (T6074, St. Louis, 
MO). Monoclonal anti-phospho-T308-AKT (4056), 
pan-AKT1/2/3 (4691), phospho-ERK1/2-T202/Y204 
(4370), pan-ERK1/2 (4695), and anti-PARP (9532) 
antibodies were purchased from Cell Signaling 
Technology (Danvers, MA). All primary antibodies 
recognize human proteins and were produced in 
rabbit. A peroxidase conjugate served as secondary 
goat anti-mouse IgG antibody (A4416, Millipore 
Sigma, Darmstadt, Germany). Cell lines were 
maintained in a humidified 5.0% CO2 incubators at 
37.0 °C (310.15 K). In order to prepare whole cell 
protein lysates, media was removed and cells were 
washed once with ice-cold PBS. After removal of PBS, 
extraction buffer was added directly to the plates and 
cells were collected with a cell scraper. Cell extracts 
were incubated on ice for 20 min. Cell debris was 
removed by centrifugation at 14,000 rpm at 4 °C 
(277.15 K) for 20 min, supernatant was collected and 
stored at -80 °C (193.15 K). 25 μg of protein was 
routinely used for Western immunoblot analysis. The 
intensity of the protein bands on the blots was 
quantified using National Institutes of Health-
approved ImageJ platform (National Institutes of 
Health, Bethesda, MA). 
Statistical analysis 
Statistical significance of experimental data 
was evaluated by a Student’s t-test or Fisher analysis 
of variance. The statistical significance thresholds was 
set at p values of *p<0.05, **p<0.01 or ***p<0.001. 
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L-glutamine deprivation and glutaminase 
inhibition 
Cells were plated in white 96-well assay 
plates at a density of 104 cells/well in 100 μL of media 
containing either no L-glutamine, 2.0 mM L-
glutamine, or 2.0 mM L-glutamine with 1.0 mM 
selective glutaminase inhibitor bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide 
(BPTES, SML0601, Sigma Merck, Darmstadt, 
Germany). After 24 h, cells were equilibrated at room 
temperature before being treated with 100 μL/well of 
CellTiter-Glo luminescent cell viability assay and 
analyzed. 
Cell culture for metabolomics measurements 
For metabolite quantification and stable 
isotope tracing, 106 cells per well were seeded in 
replicate (N=6) in 6 well plates (657160, Greiner Bio-
One, Kremsmünster, Germany) in DMEM (10-017, 
Corning Cell-Gro, Manassas, VA) supplemented with 
10% FBS, 1% Penicillin-Streptomycin (30-002-CI, 
Corning Cell-Gro, Manassas, VA), and 1% MEM Non-
Essential Amino Acids (25-025-C, Corning Cell-Gro, 
Manassas, VA). Following a 24 h seeding, attachment, 
and equilibration period, media was aspirated and 
replaced with MEM (Corning Cell-Gro, Manassas, VA) 
supplemented with 1.0 g/L D-glucose (0188, 
Amresco, Solon, OH), 2.0 mM L-Glutamine (G3126, 
Sigma Merck, Darmstadt, Germany), 10% FBS, and 1% 
MEM Vitamins (25-020-CI, Corning Cell-Gro, 
Manassas, VA). For glucose and glutamine labeling 
experiments, MEM media was supplemented with 
1.0 g/L [U-13C6] D-glucose ([U-13C6] GLC, 389374-2G, 
Sigma Isotec, Miamisburg, OH) or 2.0 mM [U-13C5] L-
glutamine ([U-13C5] GLN, 605166-500MG, Sigma 
Isotec, Miamisburg, OH). 
Metabolite extraction 
Following 24 h incubation in supplemented 
MEM, 5 μL of supernatant containing blood plasma, 
cellular samples, or conditioned media was 
transferred to microcentrifuge tubes (MT-0200-BC, 
Biotix, San Diego, CA) with 1 mL of cold -20 °C 
(253.15 K) extraction buffer consisting of 50% 
methanol (A452, Fisher Scientific, Fair Lawn, NJ) in 
ultrapure (18.2 MΩ x cm) water with 20µM L-
norvaline (N7627 Sigma Merck, Darmstadt, Germany) 
and 20µM DL-norleucine (N1398, Sigma Merck, 
Darmstadt, Germany) and dried by vacuum 
centrifugation in a speedvac concentrator 
(DNA120OP115, Savant, Thermo Fisher Scientific, 
Waltham, MA) overnight. The remaining media was 
aspirated and the cells washed quickly with cold 0.9% 
sodium chloride in ultrapure water (Amresco, Solon, 
OH) and placed on ice. To each well, 1 mL of cold 
extraction buffer was added, the cells were collected 
on ice using a cell scraper and the entire solution was 
then transferred to a pre-chilled microcentrifuge 
tube. Tubes were then frozen in liquid nitrogen, 
thawed, and placed in a digital shaking drybath (8888-
0027, Thermo Fisher Scientific, Waltham, MA) set to 
1100rpm for 15 min at 4 °C (277.15 K). Samples were 
then centrifuged for 15 min at 4 °C (277.15 K) and 
12500 g in a refrigerated centrifuge (X1R Legend, 
Sorvall, Thermo Fisher Scientific, Waltham, MA) using 
a fixed-angle rotor (F21-48x1.5, Sorvall, Thermo 
Fisher Scientific, Waltham, MA). Supernatants were 
transferred to new microcentrifuge tubes and dried 
by vacuum centrifugation overnight. 
Metabolite derivatization 
Dried, extracted plasma, cell samples or 
media supernatants were derivatized by addition of 
20 μL of 2.0% methoxyamine-hydrochloride in 
pyridine (MOX, TS-45950, Thermo Fisher Scientific, 
Waltham, MA) followed by a 90 min incubation 
period in a digital shaking drybath at 30 °C (303.15 K) 
and 1100 rpm. 90 μL of N-methyl-N-
(trimethylsilyltrifluoroacetamide (MSTFA, 394866-
10X1ML, Sigma Merck, Darmstadt, Germany) was 
added and samples incubated at 37 °C (310.15 K) and 
1100 rpm for 30 min before centrifugation for 5 min 
at 14,000 rpm and 4 °C (277.15 K). The supernatant 
was transferred to an autosampler vial (C4000LV3W, 
Thermo Fisher Scientific, Waltham, MA) with 
screwcap (C5000-53B, Thermo Fisher Scientific, 
Waltham, MA) for separation by gas chromatography 
(GC, TRACE 1310, Thermo Fisher Scientific, San Jose, 
CA) coupled to a triple-quadrupole GC mass 
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spectrometry system for analysis (QQQ GCMS, 
TSQ8000EI, TSQ8140403, Thermo Fisher Scientific, 
San Jose, CA). 
Metabolomics separation and detection 
Samples were analyzed on a QQQ GCMS 
system equipped with a 0.25 mm inner diameter, 
0.25 μm film thickness, 30 m length 5% diphenyl/95% 
dimethyl polysiloxane capillary column (OPTIMA 5 MS 
Accent, 725820.30, Machery-Nagel) and run under 
electron ionization at 70 eV. The GC was programed 
with an injection temperature of 250.0 °C (523.15 K) 
and splitless injection volume of 1.0 μL. For media 
samples, a 1:20 split injection was used. The GC oven 
temperature program started at 50 °C (323.15 K) for 
1 min, rising to 300.0 °C (573.15 K) at 10 K/min with a 
final hold at this temperature for 6 min. The GC flow 
rate with helium carrier gas (HE, HE 5.0UHP, Praxair, 
Danbury, CT) was 1.2 mL/min. The transfer line 
temperature was set at 290.0 °C (563.15 K) and ion 
source temperature at 295.0 °C (568.15 K). A range of 
50-600 m/z was scanned with a scan time of 0.25 s. 
Metabolomics data processing 
Metabolites were identified using 
TraceFinder (v3.3, Thermo Fisher Scientific, Waltham, 
MA) based on libraries of metabolite retention times 
and fragmentation patterns (Metaflux, Merced, CA). 
Identified metabolites were quantified using the 
selected ion count peak area for specific mass ions, 
and standard curves generated from reference 
standards run in parallel. Peak intensities were 
normalized for extraction efficiency using L-norvaline 
as an internal standard. The mean and standard 
deviation for each quantified metabolite was 
calculated for each cell line and treatment condition. 
A univariate t-test was used to compare treatment 
conditions for each metabolite and cell line. 
Results 
Metabolic profiling of a melanoma 
progression model with activated glutamatergic 
signaling 
GRM1-positive melanoma patients share a 
common metabolic dysregulation in glutamatergic 
signaling. In contrast, the common genotype of 
melanoma involves mutations of the MAPK pathway, 
including mutually exclusive mutations of BRAF-, 
NRAS-, and NF1 40,41. In case MAPK driver mutations 
are lacking, the genotype is classified as 
NF1/NRAS/BRAF triple negative or triple wild-type 
subtype and remains without actionable molecular 
targets. Overcoming the lack of molecular targets of 
this subtype has been identified as one of the prime 
goals of the melanoma and pigment cell research 
community 14. In order to understand and quantify 
the metabolic phenotype of GRM1-activated (GRM1+) 
cells, we profiled an isogenic cellular melanoma 
model by GCMS (Figure 1). 
Quantifying the intracellular glutamate pool 
The panel includes non-tumorigenic models, 
C81-61 (GRM1—) and C8161si (GRM1KD), vs 
tumorigenic models, C81-61OE (GRM1OE) and C8161 
(GRM1+) (Figure 1A). Several studies have shown that 
cells expressing GRM1 produce greater amounts of 
glutamate 10,30-32. To determine the effect of GRM1 on 
the intracellular pool size of glutamate, we incubated 
C81-61, C8161si, C81-61OE, and C8161 melanoma 
cell lines in glutamate free media and measured 
intracellular glutamate via gas chromatography mass 
spectrometry (GCMS). In accordance with previous 
results, cells with greater GRM1 expression (C81-
61OE and C8161) had significantly increased levels of 
intracellular glutamate than did their counterparts 
with low GRM1 expression (C81-61 and C8161si) 
(Figure 1B). Hierarchical clustering of specimens 
identified two major branches, which resembled 
tumorigenicity in the melanoma progression model 
(Figure 1C). C81-61OE (GRM1OE) and C8161 (GRM1+) 
showed a cluster characterized by elevated pool sizes 
of glutamate and tricarboxylic acid (TCA) cycle related 
metabolites. Among the strongest dysregulated 
metabolites are α-ketoglutaric acid, aspartic acid, 
fumaric acid, malic acid, asparagine, trans-4-
hydroxyproline, lysine, glutamic acid, and citric acid. 
There metabolites are significantly elevated in the 
tumorigenic specimens with p values below 10-3. 
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Significantly enriched and associated pathways with 
this cluster of metabolites include the TCA cycle, 
glutamate metabolism, aspartate metabolism, as well 
as arginine and proline metabolism with p values 
below 10-3. A principle component analysis converts 
the set of biochemically possibly correlated 
metabolite variables into a set of linearly 
uncorrelated variables called principal components. 
The principle component analysis plot includes more 
than 60% data representation in the first two 
principle components. The multidimensionality 
reduction plot visualizes the data separation between 
tumorigenic and non-tumorigenic specimens as well 
as the metabolic switch and reversal that is induced 
by the genetic perturbations (Figure 1D). Knockdown 
of GRM1 in tumorigenic C8161 causes a shift in the 
metabolic state that is similar to C81-61. In reverse, 
overexpression of GRM1 in non-tumorigenic C81-61 
causes metabolic perturbation into a quadrant of the 
multidimensional space overlapping with C8161. 
Taken together, unsupervised clustering and principle 
component analysis showed metabolic similarity 
between tumorigenic C8161 (GRM1+) and C81-61OE 
(GRM1OE) and specimens and non-tumorigenic C81-
61 (GRM1—) and C8161si (GRM1KD). Further, the 
metabolomic profiling revealed elevated levels of 
glutamate and TCA cycle-related metabolites in a 
cancer progression model of malignant melanoma. 
Stable isotope tracing of isogenic cancer 
progression model shows increased glycolytic flux into 
glutamate 
Next, we determined the relative 
contribution of glucose and glutamine to the 
intracellular glutamate pool by incubating cells with 
13C labeled tracers and measuring isotopic 
incorporation into glutamate by GCMS (Figure 2). 
C8161 (GRM1+) specimens had elevated pyruvate and 
lactate production, consistent with the Warburg 
effect of cancer cells and their proliferative 
phenotype (Figure 2A). Stable isotope incorporation 
into the M+3 feature of pyruvate from uniformly 
labeled ([U-13C6]) glucose indicates increased 
glycolytic flux in GRM1-activated tumors. While the 
intracellular pool size increased moderately, the 
biosynthetic rate increased by more than two-fold 
with a p value below 10-3. By considering the mass 
contribution of the carbon source and the tracer-to-
tracee ratio, flux into a metabolite can be calculated 
(Figure 2B). Unexpectedly, while GRM1 expression 
increased both glycolytic and glutaminolytic flux, the 
proportional increase in glycolytic glutamate was 
much higher in C8161 (GRM1+) cells. Following a 24 
hour labeling period with either uniformly labeled 
13C6-labeled glucose or uniformly labeled 13C5-
glutamine, cells with higher GRM1 expression had 
significantly higher levels of 13C-labeled glutamate 
from glucose than from cells with low GRM1 
expression (Figure 2C). Conversely, cells with high 
GRM1 expression had a lower percentage of labeled 
glutamate following incubation with 13C5-glutamine 
(Figure 2D). In summary, stable isotope labeling 
revealed increased glycolytic flux into glutamate in 
cells with high GRM1 expression. Interestingly, the 
total contribution of glutamine to the glutamate pool 
varied much less with GRM1 expression, indicating 
that GRM1 expression has a greater impact on 
glycolytic glutamate production than on glutamate 
production from glutamine. Taken together, 13C 
labeling in combination with stable isotope tracing 
identifies glucose and glutamine as distinct carbon 
sources of oncogenic glutamate, thus providing a 
rationale for metabolic drug targeting of tumorigenic 
cancer cells (Figure 2F). 
Pharmacogenomics screen of chemical 
inhibitors of metabolism 
A pharmacogenomics screen quantified the 
impact of small molecules on viability and central 
carbon metabolism in the melanoma progression 
panel (Table 1, Figure 2F). IC50 values, the dose which 
is lethal to 50% of cells, was determined for the non-
tumorigenic C81-61 (GRM1—) and tumorigenic C8161 
(GRM1+) models (Figure 2G). For each metabolic 
inhibitor compound, a two-fold dilution series in 
quadruplicate measurement over a 24-hour 
incubation period was for assessed for cell viability by 
a luminescence-based cell viability assay (Figure 2G). 
Despite the therapeutic window, defined as 
difference in drug response between cancer and 
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control cell lines, differed greatly for each compound 
tested, the sensitivity to metabolic inhibitors overall 
increased with enhanced GRM1 expression. 
Drug sensitivity of GRM1 to glutamate 
restriction 
Compounds riluzole, BPTES and CB839 
target the metabolic proximity and five-carbon supply 
of glutamate by restricting metabolic exchange of 
glutamate or conversion from glutamine to glutamate 
in the GLS reaction 42. C8161 (GRM1+) cells were more 
sensitive to riluzole, a similar response between C81-
61 (GRM1—) and C8161 (GRM1+) was observed at 
eight-fold lower concentrations of riluzole, lowering 
its IC50 value for C8161 (GRM1+) into the low 
micromolar range. To test the importance of 
glutaminolysis in GRM1+ cells, we quantified cell 
viability in the presence of BPTES and CB839, selective 
inhibitors of GLS. For BPTES a trend of lower cell 
viability with higher GRM1 expression was noted, yet 
overall, across any concentrations tested, no 
significant difference was noted in cell viability 
between C81-61 (GRM1—) and C8161 (GRM1+) cells. 
Importantly, this result deviated from another more 
potent GLS inhibitor, CB839, which showed a more 
than two-fold increase in sensitivity in the 
tumorigenic cell line and an IC50 value in the high 
nanomolar range (Table 1, Figure 2G). 
Metabolic bottleneck of glycolytic acetyl-CoA 
for TCA cycle-dependent glutamate production 
Given the increased dependence of 
tumorigenic GRM1+ cells on glycolytic carbon for 
glutamate production, we next sought to investigate 
whether inhibiting glycolysis preferentially affects the 
viability of GRM1+ cells. Incubation of cells with 2-
deoxy-glucose, a competitive inhibitor of hexokinase 
and glycolysis, and oxamate, a competitive inhibitor 
of lactate dehydrogenase (LDH) vital for reduction 
equivalent regeneration, showed that the 
tumorigenic cell line is more sensitive to inhibition of 
glycolysis than the non-tumorigenic parental cell line. 
Similarly, when incubated with UK5099, a potent 
inhibitor of the mitochondrial pyruvate transporter 
(MPC1), the tumorigenic cell line was considerably 
more sensitive than the non-tumorigenic parental cell 
line. In addition, the HIF1A modulator, deferoxamine 
mesylate stronger affected the tumorigenic cell line. 
These results indicate an increased reliance on the 
glycolysis in GRM1+ cells and that decoupling cytosolic 
glycolysis from the mitochondrial TCA cycle 
preferentially affects GRM1+ cells. 
Experimental design of preclinical 
combination trial focused on metabolic signaling and 
tumor metabolism of malignant melanoma. 
The goal of this preclinical study was to 
assess alterations in tumor progression following 
treatment of tumor-bearing mice with metabolic 
inhibitors vs control cohorts (Figure 3). In this gender-
controlled xenograft study, a randomized cohort of 
male and female animals was injected with either 
female (C8161) or male (1205LU) tumors. The tumor 
burden in the presence of control vehicle DMSO, 
riluzole at 10 mg/kg per os (p.o.), UK5099 3 mg/kg 
p.o., and CB839 200 mg/kg p.o., as well as 
combinations of riluzole with UK5099 or CB839 was 
monitored. 
Significant reduction of tumor burden in 
combination modality of different metabolic drugs 
targeting glutamate bioavailability 
Tumor burden in xenograft models was 
monitored in a gender-controlled study over the time 
of 28 days, comparing drug single treatment 
conditions vs combination treatments and control 
vehicle. Tested drug conditions included single 
treatments of riluzole, UK5099, CB839, as well as 
riluzole combined with UK5099 or CB839 (Figure 3). 
In the C8161 tumor model, the combination modality 
of riluzole and CB839 performed best, while the 
combination of riluzole and UK5099 did not improve 
a reduction of tumor burden (Figure 4A,B). Given 
these results, in a second large cohort modalities with 
UK5099 were excluded. The 1205LU xenografts were 
treated with single treatments of riluzole or CB839, as 
well as a combination modality of riluzole with CB839. 
Validating the C8161 tumor xenografts, the 1205LU 
xenografts responded best to the combination 
modality with riluzole and CB839 (Figure 4C,D). 
_____________________________________________________________________________________ 
GRM1  Page 9 of 15 
Sex-specific response in tumor xenograft 
models 
The experimental design included gender-
specific xenograft models allowing to assess the 
impact of cross-sex tumor xenografts (e.g. CB161 
tumors into male mice or 1205LU tumors into female 
mice) in comparison with same-sex tumor xenografts 
(e.g. CB161 tumors into female mice or 1205LU 
tumors into male mice). The data showed an overall 
reduction of the tumor burden under single 
treatment for cross-sex xenografts. In contrast, the 
impact of combination treatments in comparison to 
single treatments was much more pronounced in 
same-sex treatments. For example, in 1205LU 
xenografts in female mice, the combination of riluzole 
and CB839 was comparable to CB839, which already 
had high efficacy alone. Overall, the comparison of 
different xenograft systems showed that no single 
agent treatment was as effective as the combination 
modality of riluzole with CB839 in reducing tumor 
progression (Figure 4). Single agent CB839 had the 
best efficacy, followed by riluzole. In contrast, mice 
treated with UK5099 as single or combination 
modality showed the least effectiveness in reducing 
tumor volumes but rather suffered from weight loss 
during the study. Also the addition of riluzole to 
UK5099 did not alter the outcome. In contrast, the 
combination of riluzole and CB839 significantly 
improved the reduction of tumor burden over vehicle 
control and in comparison with single treatments 
(Figure 4). The preclinical data on tumor burden 
identified the combination of riluzole and CB839 as 
the most effective therapeutic strategy tested. 
Further, results from these in vivo studies uncovered 
a gender effect in tumor xenograft studies. An 
enhanced treatment efficacy was observed if donor 
tumor cells and the gender of the recipient mice 
match (Figure 4). 
Molecular pathology characterizing cell 
proliferation, apoptosis, and glutamatergic signaling 
in excised xenograft tumors 
Immunohistochemistry allowed for 
assessment of cancer signaling by looking at the 
overall expression levels of a given marker. The drug-
treated tumor tissues showed a significant reduction 
in protein expression of the oncogenic driver GRM1. 
In contrast, the vehicle-treated control displays high 
level of GRM1 protein. Mitogenic signaling pathways 
associated with MAPK and AKT exhibit reduced 
activation of key stimulatory factors including 
phospho mitogen-activated protein kinase 1 
(MAPK1/ERK) and phospho AKT. GLS, the protein 
target of CB839 shows reduced expression in riluzole 
and the combination modality. In contrast, the single 
treatment of CB839 displays high levels of GLS 
comparable to pre-treatment levels, pointing to 
heterogeneity and potential counter regulation of 
GLS at the protein level. Histopathology staining for 
apoptosis and proliferation provided insight into 
tissue and tumor response under treatment in 
context of normal and tumor cells. Histopathology 
staining monitored MKI67 as marker of proliferation 
of tumor cells and cleaved caspase 3 (CASP3) 
indicative of apoptosis under drug treatment. Overall, 
the combination treatment of riluzole with CB839 
reduced expression of proliferation markers and pro-
survival proteins (Figure 5). The histopathological 
assessment of the drug trial also included staining of 
liver sections with hematoxylin and eosin. 
Histopathology of the liver did not reveal inflamed or 
necrotic regions of the tissue indicating tolerance of 
the utilized drug dosages. 
Reduction of plasma amino acid metabolite 
pool sizes upon combination treatment with GRM1 
inhibitor riluzole and glutaminase inhibitor CB839 
Glutamate plasma levels respond to the 
administered drugs. Circulating glutamate of tumor 
xenografts is significantly lowered by about 20% on 
average upon combination treatment with GRM1 
inhibitor riluzole and glutaminase inhibitor CB839 
with p values below 0.05 (Figure 6). In addition, 
anaplerotic amino acids and TCA cycle-related 
organic acids belong to the direct supply chain of 
biosynthetic tumor glutamate and the tumor 
microenvironment. Targeted metabolomics revealed 
that plasma pool sizes of hydroxyl-proline, 
oxoglutarate, oxalic acid, aspartate, and asparagine 
showed significant reduction in the combination 
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treatment with p values below 10-3 (Figure 6). Their 
profiles indicate a trend of higher responsiveness of 
plasma metabolite from single treatment with 
riluzole to single treatment with CB839 and maximum 
response in the combination modality of both drugs 
combined. 
Discussion 
Tumor models of rewired glutamate 
metabolism provide a unique focus on noncanonical 
mitogen-activated protein kinase pathways, G-
protein activation independent of 
NF1/BRAF/NRAS/MAPK genotypes, and metabolic 
signaling in cancer. In melanoma, hyperactive 
metabotropic glutamate receptor 1 (GRM1) is an 
oncogenic driver in the neuroectodermal-derived 
lineage of melanocytes. Ectopic expression of G 
protein-coupled receptors have the ability to regulate 
mitogenic signals 16,43. A switch to cell cycle 
progression and biosynthetic metabolism creates 
overflow metabolism, which in turn produces the 
extracellular signals required for stimulation of the 
ectopic transmembrane receptors. GRM1-positive 
cancer cells release excess glutamate into the 
extracellular environment, leading to constitutive 
activation of the receptor. Thus, in melanoma, GRM1+ 
tumors have acquired a self-stimulatory feedback 
loop, which is challenging to overcome by 
pharmacological targeting efforts. GRM1 activation is 
independent but not mutually exclusive to frequently 
observed activating BRAF mutations in melanoma 44. 
Effective genotype-matched targeting identified the 
oncogenic event, involves suppression of the 
signaling cascade, controls biosynthetic production of 
effector molecules, and break positive enforcement 
of existing feedback circuits. In detail, the identified 
combination modality targeting rewired glutamate 
signaling in melanoma showed reduced expression of 
the identified upstream G protein-coupled receptor 
and cancer driver GRM1 itself. Furthermore, it 
reduced mitogenic mediators phospho-AKT and 
phospho-ERK 43, suppressed the glutamate-fueling 
enzyme GLS 44, and restricted overflow metabolism of 
glutamate into circulation and tumor 
microenvironment, thereby keeping the effector 
molecule and feedback trigger, glutamate, in check. 
Riluzole and CB839 aim at complementary 
aspects of glutamate signaling and metabolism. 
Riluzole has been established as functional inhibitor 
of the cystine-glutamate antiporter system solute 
carrier family 7 member 11 (SLC7A11, xCT) preventing 
release of excess glutamate 45. In the treatment of 
amyotrophic lateral sclerosis (ALS), riluzole contains 
neurotoxic excretion of glutamate 46. Glutaminase 
inhibitors are currently evaluated as chemotherapy 
agents for patients with advanced, metastatic solid 
and hematopoietic tumors 47,48, where glutamine 
metabolism has been identified as suitable drug 
target—even in the absence of hyperactive glutamate 
biosynthesis. Based on tumor burden and molecular 
pathology, our data evidence that the combination of 
glutamate release inhibitor riluzole and GLS inhibitor 
CB839 is superior to single drug modalities. In the 
xenografts tested, the combination treatment was 
tolerated well and even led in few instances to 
complete elimination of the tumor mass in the 
absence of systemic toxicities. 
The aspect of gender origin of cells utilized in 
experimental biology has been recognized as 
important determinant and human cells exhibit wildly 
different concentrations of many metabolites across 
the sexes 49,50. We identified two sex-related aspects 
in xenograft models contributing to different drug 
efficacy. The first aspect addresses matching sex 
between donor tumor specimen and host animal. 
Potential barriers imposed by immune recognition, 
cell-to-cell communication, and hormone-dependent 
signaling may favor elimination of cells with less 
similar genotypes, leading to reduced engraftment. 
Tumors injected into a host animal of the opposite 
gender yielded a significantly reduced tumor burden. 
A second layer addresses cytotoxicity of a drug, which 
may be different for each gender depending on 
differences in xenobiotic metabolism 51. Further, 
when looking at an absolute quantity like tumor 
volume upon drug treatment, such cross-sex related 
modulation of the engraftment efficacy may lower 
the reported drug efficacy across a cohort average in 
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the absence of gender stratification. By rigorously 
implementing gender stratification, personalized 
treatment regimens are facilitated and 
reproducibility of disease and developmental models 
is enabled, consistent with the mandate from the 
National Institutes of Health to improve scientific 
rigor and reproducibility in research. 
Pharmacogenomics and systems biology 
suggest that the relationships between the cellular 
response to drugs, genetic variation of patients and 
cell metabolism may facilitate managing side effects 
by personalizing drug prescriptions and nutritional 
intervention strategies. Genome-wide modeling of 
drug responses in human flux models have shown 
that it is possible to predict pathways or closely 
related metabolic sub-networks responsive to small 
molecule inhibition 52. In future, computational 
prediction will substantially accelerate the drug 
discovery pipeline. Along the same lines, utilization of 
in silico and cellular models in pharmacogenomics 
allows high throughput screening and exclusion of 
less promising drug conditions before entering clinical 
trials. Still, foreseeing success or failure when 
translating in vitro models to in vivo pharmacokinetics 
is challenging. Our experimental design and rational 
drug screening pipeline considered metabolic 
profiling of pathway responses, stable isotope tracing 
of carbon sources of production metabolites, and 
plate-based toxicology screens of drug responses. 
Using stable isotope tracing and GCMS analysis, we 
determined that cells expressing GRM1 fuel carbon in 
glutamate from glucose and glutamine. Furthermore, 
the glycolytic contribution into glutamate is increased 
compared to normal cells. The increased dependence 
of glycolytic carbon for glutamate production is 
further confirmed by the enhanced sensitivity of 
GRM1 expressing cells to inhibitors that block the 
anaplerotic flow of carbon into the mitochondrial TCA 
cycle metabolite pool. UK5099 targeted glycolytically-
derived glutamate influx, restrained the bottleneck of 
mitochondrial pyruvate supply, and significantly 
reduced the drug response from non-tumorigenic to 
tumorigenic specimens. Based on outlined criteria, 
the compound was a promising lead and top in vitro 
performing compound of the drug panel tested. In 
contrast, treatment with UK5099 did not alleviate the 
tumor burden in xenografted animals. The fact that 
mice in the UK5099 treated group exhibited weight 
loss and behavioral effects indicates a significant 
bioenergetic impact. However, unexpectedly 
blockade of the mitochondrial pyruvate carrier 
eventually benefitted tumor metabolism, selecting 
for a rewired metabolic state favoring extensive 
tumor growth and resulting in higher tumor burden 
instead of reducing it. Notably, further increase of 
drug dosage was not possible due to apparent side 
effects. 
Our drug targeting strategy considered 
different aspects of tumor metabolism. The goal of 
the study was to cut off glutamate supply, while 
reducing circulating glutamate plasma levels, such 
that the mitogenic glutamatergic feedback loop can 
be broken. The combined treatment of riluzole and 
CB839 leads to enhanced inhibition of GRM1+ 
melanoma proliferation and reduction of tumor 
burden in vivo. The animal models evidenced 
significant suppression of tumor progression, in part 
complete relieve of the tumor, following treatment 
with the combination of riluzole and CB839. The 
ability to generate glutamate from glucose confers 
adaptive advantage to GRM1 activated and 
dependent cells, particularly those existing in 
glutamine poor microenvironments. However, in vivo 
experiments showed that limiting glycolytic carbon 
supply via the mitochondrial pyruvate carrier into the 
TCA cycle is insufficient. Back-to-back comparison of 
in vivo inhibitor combinations evidenced that 
inhibition of glutaminolytic carbon has higher efficacy 
in comparison to glycolytic carbon sources.  
By following the flow of carbon from glucose 
and glutamine in GRM1 expressing melanoma, we 
have identified fundamental metabolic pathways that 
support autocrine glutamatergic signaling. Rational 
targeting of these pathways therefore provides novel 
combinatorial treatment focused on glutaminases 
and glutamate release inhibitors in the treatment of 
GRM1 expressing malignancies. 
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Conclusion 
Stable isotope tracing and GCMS analysis 
revealed that expression of the metabotropic 
glutamate receptor GRM1 leads to an increase in the 
production of glutamate in melanoma cells. Though it 
has been thought that increased glutamine uptake 
and glutaminolysis is responsible for increased 
glutamate production, our results indicate an 
important role for glycolysis and glucose derived 
glutamate in cells expressing GRM1. In fact, while 
GRM1 expression increases the overall amount of 
glutamate produced the proportion of glucose versus 
glutamine derived glutamate is increased. This data 
was supported by an increased sensitivity to 
inhibitors of glycolytic metabolism in cells over 
expressing GRM1. Together, these results suggest 
that targeting increased glutamate production from 
glutaminolytic and glycolytic sources may be an 
effective treatment for GRM1 expressing melanoma. 
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Figure 1: Metabolomic profiling of isogenic 
cancer progression model 
 
Figure 2: Stable isotope tracing identifies 
dual carbon source and directs metabolic targeting of 
tumorigenic cancer cells 
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Figure 3: Preclinical combination trial targets 
metabolic signaling and tumor metabolism of 
malignant melanoma 
 
Figure 4: The combination modality of 
riluzole and CB839 significantly reduces tumor 
burden vs vehicle control or single treatment 
 
Figure 5: Molecular characterization of 
tumor xenografts under drug treatment 
 
Figure 6: Reduction of circulating metabolite 
levels in combination modality of riluzole and CB839 
targeting GRM1 activated melanoma 
Table 1: Pharmacogenomics screen 
targeting rewired metabolism in melanoma. 
compoun
d 
metabolic 
effect 
IC50 non-
tumorigenic 
C81-61 
(GRM1—) 
IC50 
tumorigeni
c C8161 
(GRM1+) 
a = 
riluzole 
inhibits 
GRM1 
152.03 μM 19.50 μM 
b = BPTES inhibits 
glutamina
se 
9.55 μM 5.98 μM 
c = CB839 inhibits 
glutamina
se 
505.0 nM 222.0 nM 
d = 
UK5099 
inhibits 
mito 
pyruvate 
carrier 
420.0 nM 4.7 nM 
e = 
dicloroac
etate 
inhibits 
PDK, 
activates 
PDH 
113.068 mM 114.665 m
M 
f = 
oxamate 
inhibits 
LDH 
40.027 mM 9.133 mM 
g = 2-
deoxyglu
cose 
inhibits 
HK 
5.518 mM 3.796 mM 
h = 
deferoxa
mine 
mesylate 
stabilizes 
HIF1A 
161.19 μM 142.93 μM 
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